Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 5
---
 accompanying Series L Warrants, as the case may be, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. Pursuant to the registration statement related to this prospectus, we are also registering the Depositary Shares issuable upon exercise of the Series L Warrants and Pre-Funded Warrants included in the Units and Pre-Funded Units offered hereby.

For
each Pre-Funded Unit we sell (without regard to any limitation on exercise set forth therein), the number of Units we are offering will
be decreased on a one-for-one basis. Because a Series L Warrant is being sold together in this offering with each Depositary Share and,
in the alternative, each Pre-Funded Warrant to purchase one Depositary Share, the number of Series L Warrants sold in this offering will
not change as a result of a change in the mix of the Depositary Shares and Pre-Funded Warrants sold.

Our Depositary Shares are
listed on the NASDAQ Capital Market under the symbol “BDRX.” On , 2025, the last reported sale price of our Depositary Shares
on the NASDAQ Capital Market was $ per share. All Depositary Share, Pre-Funded Warrant and Series L Warrant numbers are based on an assumed
combined public offering price of $ per Unit. The actual public offering price will be determined through negotiation between us and the
underwriters in the offering and may be at a discount to the current market price. Therefore, the assumed combined public offering price
used throughout this prospectus may not be indicative of the final public offering price.

The
Units have no stand-alone rights and will not be certificated or issued as stand-alone securities.

There
is no established trading market for the Units, Pre-Funded Units, Series L Warrants or Pre-Funded Warrants, and we do not expect a market
to develop. In addition, we do not intend to apply for the listing of the Pre-Funded Warrants or Series L Warrants on any national
securities exchange or other trading market. Without an active trading market, the liquidity of these securities will be limited.

This
offering will terminate on , 2025, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to
such date.

<div align='center'>Confidential Treatment Requested by Biodexa Pharmaceuticals PLC

Pursuant to 17 C.F.R. Section 200.